673 related articles for article (PubMed ID: 27068454)
81. A replicating adenovirus capsid display recombinant elicits antibodies against Plasmodium falciparum sporozoites in Aotus nancymaae monkeys.
Karen KA; Deal C; Adams RJ; Nielsen C; Ward C; Espinosa DA; Xie J; Zavala F; Ketner G
Infect Immun; 2015 Jan; 83(1):268-75. PubMed ID: 25368113
[TBL] [Abstract][Full Text] [Related]
82. Restricted T-cell epitope diversity in the circumsporozoite protein from Plasmodium falciparum populations prevalent in Iran.
Zakeri S; Avazalipoor M; Mehrizi AA; Djadid ND; Snounou G
Am J Trop Med Hyg; 2007 Jun; 76(6):1046-51. PubMed ID: 17556609
[TBL] [Abstract][Full Text] [Related]
83. Strain-transcending neutralization of malaria parasite by antibodies against Plasmodium falciparum enolase.
Dutta S; Tewari A; Balaji C; Verma R; Moitra A; Yadav M; Agrawal P; Sahal D; Jarori GK
Malar J; 2018 Aug; 17(1):304. PubMed ID: 30126436
[TBL] [Abstract][Full Text] [Related]
84. Preclinical efficacy and immunogenicity assessment to show that a chimeric Plasmodium falciparum UB05-09 antigen could be a malaria vaccine candidate.
Dinga JN; Gamua SD; Ghogomu SM; Titanji VPK
Parasite Immunol; 2018 Mar; 40(3):. PubMed ID: 29284177
[TBL] [Abstract][Full Text] [Related]
85. Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer.
Miura K; Keister DB; Muratova OV; Sattabongkot J; Long CA; Saul A
Malar J; 2007 Aug; 6():107. PubMed ID: 17686163
[TBL] [Abstract][Full Text] [Related]
86. The challenges of a circumsporozoite protein-based malaria vaccine.
Chatterjee D; Cockburn IA
Expert Rev Vaccines; 2021 Feb; 20(2):113-125. PubMed ID: 33554669
[TBL] [Abstract][Full Text] [Related]
87. Recombinant Mycobacterium bovis BCG producing the circumsporozoite protein of Plasmodium falciparum FCC-1/HN strain induces strong immune responses in BALB/c mice.
Zheng C; Xie P; Chen Y
Parasitol Int; 2002 Mar; 51(1):1-7. PubMed ID: 11880222
[TBL] [Abstract][Full Text] [Related]
88. Antibody interference by a non-neutralizing antibody abrogates humoral protection against Plasmodium yoelii liver stage.
Vijayan K; Visweswaran GRR; Chandrasekaran R; Trakhimets O; Brown SL; Watson A; Zuck M; Dambrauskas N; Raappana A; Carbonetti S; Kelnhofer-Millevolte L; Glennon EKK; Postiglione R; Sather DN; Kaushansky A
Cell Rep; 2021 Aug; 36(5):109489. PubMed ID: 34348141
[TBL] [Abstract][Full Text] [Related]
89. Extended protection capabilities of an immature dendritic-cell targeting malaria sporozoite vaccine.
Luo K; Zavala F; Gordy J; Zhang H; Markham RB
Vaccine; 2017 Apr; 35(18):2358-2364. PubMed ID: 28342669
[TBL] [Abstract][Full Text] [Related]
90. Development of two monoclonal antibodies against Plasmodium falciparum sporozoite surface protein 2 and mapping of B-cell epitopes.
Charoenvit Y; Fallarme V; Rogers WO; Sacci JB; Kaur M; Aguiar JC; Yuan LF; Corradin G; Andersen E; Wizel B; Houghten RA; Oloo A; De la Vega P; Hoffman SL
Infect Immun; 1997 Aug; 65(8):3430-7. PubMed ID: 9234808
[TBL] [Abstract][Full Text] [Related]
91. Induction of protective immunity against malaria by priming-boosting immunization with recombinant cold-adapted influenza and modified vaccinia Ankara viruses expressing a CD8+-T-cell epitope derived from the circumsporozoite protein of Plasmodium yoelii.
González-Aseguinolaza G; Nakaya Y; Molano A; Dy E; Esteban M; Rodríguez D; Rodríguez JR; Palese P; García-Sastre A; Nussenzweig RS
J Virol; 2003 Nov; 77(21):11859-66. PubMed ID: 14557672
[TBL] [Abstract][Full Text] [Related]
92. Plasmodium yoelii macrophage migration inhibitory factor is necessary for efficient liver-stage development.
Miller JL; Harupa A; Kappe SH; Mikolajczak SA
Infect Immun; 2012 Apr; 80(4):1399-407. PubMed ID: 22252874
[TBL] [Abstract][Full Text] [Related]
93. A Potent Anti-Malarial Human Monoclonal Antibody Targets Circumsporozoite Protein Minor Repeats and Neutralizes Sporozoites in the Liver.
Wang LT; Pereira LS; Flores-Garcia Y; O'Connor J; Flynn BJ; Schön A; Hurlburt NK; Dillon M; Yang ASP; Fabra-García A; Idris AH; Mayer BT; Gerber MW; Gottardo R; Mason RD; Cavett N; Ballard RB; Kisalu NK; Molina-Cruz A; Nelson J; Vistein R; Barillas-Mury C; Amino R; Baker D; King NP; Sauerwein RW; Pancera M; Cockburn IA; Zavala F; Francica JR; Seder RA
Immunity; 2020 Oct; 53(4):733-744.e8. PubMed ID: 32946741
[TBL] [Abstract][Full Text] [Related]
94. Immunization with recombinant Plasmodium yoelii merozoite surface protein 4/5 protects mice against lethal challenge.
Kedzierski L; Black CG; Coppel RL
Infect Immun; 2000 Oct; 68(10):6034-7. PubMed ID: 10992516
[TBL] [Abstract][Full Text] [Related]
95. Preliminary studies on the immunogenicity of a prime-and-trap malaria vaccine in nonhuman primates.
Shears MJ; Watson FN; Stone BC; Cruz Talavera I; Parthiban C; Matsubara J; Kc N; Sim BKL; Hoffman SL; Murphy SC
Vaccine; 2023 Aug; 41(38):5494-5498. PubMed ID: 37563050
[TBL] [Abstract][Full Text] [Related]
96. Alga-produced malaria transmission-blocking vaccine candidate Pfs25 formulated with a human use-compatible potent adjuvant induces high-affinity antibodies that block Plasmodium falciparum infection of mosquitoes.
Patra KP; Li F; Carter D; Gregory JA; Baga S; Reed SG; Mayfield SP; Vinetz JM
Infect Immun; 2015 May; 83(5):1799-808. PubMed ID: 25690099
[TBL] [Abstract][Full Text] [Related]
97. Characterization of two in vivo challenge models to measure functional activity of monoclonal antibodies to Plasmodium falciparum circumsporozoite protein.
Raghunandan R; Mayer BT; Flores-Garcia Y; Gerber MW; Gottardo R; Jhun H; Herrera SM; Perez-Ramos DW; Locke E; King CR; Zavala F
Malar J; 2020 Mar; 19(1):113. PubMed ID: 32183833
[TBL] [Abstract][Full Text] [Related]
98. Artesunate versus chloroquine infection-treatment-vaccination defines stage-specific immune responses associated with prolonged sterile protection against both pre-erythrocytic and erythrocytic Plasmodium yoelii infection.
Peng X; Keitany GJ; Vignali M; Chen L; Gibson C; Choi K; Huang F; Wang R
J Immunol; 2014 Aug; 193(3):1268-77. PubMed ID: 24958899
[TBL] [Abstract][Full Text] [Related]
99. Daily Plasmodium yoelii infective mosquito bites do not generate protection or suppress previous immunity against the liver stage.
Pollock T; Leitao R; Galan-Rodriguez C; Wong KA; Rodriguez A
Malar J; 2011 Apr; 10():97. PubMed ID: 21501513
[TBL] [Abstract][Full Text] [Related]
100. Members of the merozoite surface protein 7 family with similar expression patterns differ in ability to protect against Plasmodium yoelii malaria.
Mello K; Daly TM; Long CA; Burns JM; Bergman LW
Infect Immun; 2004 Feb; 72(2):1010-8. PubMed ID: 14742548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
